Andere talen Kineta, Inc.

Aandelen

KA

US49461C1027

Geschatte realtime Cboe BZX Andere beurzen 21:12:21 09-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,65 ^USD	+14,64%		+14,05%	-82,37%

08/04	Kineta, Inc. rapporteert op AACR 2024 de eerste klinische responsgegevens van het lopende Fase 1/2 Vista-101 klinische onderzoek	CI
12/03	Kineta, Inc. Kondigt een update aan van het lopende Vista-101 Fase 1/2 klinische onderzoek waarin Kva12123 wordt geëvalueerd	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial	08/04
Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	08/04
Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M	21/03
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update	21/03
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported	12/03
Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123	12/03
Top Midday Decliners	29/02
Kineta Announces Restructuring and Exploration of Strategic Alternatives	29/02
Kineta, Inc. Terminates Employment of Pauline Kenny as General Counsel and Secretary	29/02
Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO	29/02
Kineta, Inc. Announces Restructuring and Workforce Reduction	29/02
Kineta Announces Exploration of Strategic Alternatives	29/02
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium	22/02
Kineta to Present at Upcoming Investor Conferences	14/02
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series	07/02
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors	17/01
Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity	17/01
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event	04/01
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer	13/12
Kineta to Present at the Life Sciences Investor Forum December 14th	12/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kineta, Inc.

Aandelen

KA

US49461C1027

Andere talen

Filters